News stories about INC Research (NASDAQ:SYNH) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. INC Research earned a news impact score of 0.03 on Accern’s scale. Accern also assigned headlines about the company an impact score of 42.7914673118243 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
Shares of INC Research (NASDAQ SYNH) opened at $37.00 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. The firm has a market capitalization of $3,860.00, a price-to-earnings ratio of -64.91, a PEG ratio of 1.08 and a beta of 0.80. INC Research has a 52-week low of $33.60 and a 52-week high of $61.10.
SYNH has been the topic of several recent research reports. TheStreet raised INC Research from a “c” rating to a “b-” rating in a research report on Monday, November 6th. Robert W. Baird cut INC Research to an “outperform” rating and dropped their target price for the company from $67.00 to $46.00 in a research report on Friday, November 10th. Jefferies Group reaffirmed a “buy” rating and set a $55.00 target price on shares of INC Research in a research report on Friday, November 10th. KeyCorp reissued a “market perform” rating and issued a $46.00 price objective (down previously from $68.00) on shares of INC Research in a research report on Monday, November 13th. Finally, Credit Suisse Group lowered their price objective on INC Research from $68.00 to $54.00 and set an “outperform” rating for the company in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $50.78.
In other news, CAO Christopher L. Gaenzle sold 1,470 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $41.00, for a total value of $60,270.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.24% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-inc-research-synh-stock-price.html.
INC Research Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.